Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - suppositorien - mesalazinum 1000 mg, adeps solidus, pro suppositorio. - la colite ulcerosa - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - compresse rivestite con film - mesalazinum 250 mg, natrii carbonas, glycinum, povidonum k 25, cellulosum microcristallinum, silica colloidalis anhydrica, calcii stearas, hypromellosum, Überzug: acidi methacrylici et ethylis acrylatis polymerisatum 1:1, macrogolum 6000, talcum, copolymerum methacrylatis butylati basicum, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 47.72 mg. - la colite ulcerosa - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - compresse rivestite con film - mesalazinum 500 mg, natrii carbonas, glycinum, povidonum k 25, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, calcii stearas, hypromellosum, macrogolum 6000, Überzug: acidi methacrylici et methylis methacrylatis polymerisatum 1:1, copolymerum methacrylatis butylati basicum, talcum, macrogolum 6000, e 171, e 172 (flavum), pro compresso obducto corresp. natrium 49 mg. - la colite ulcerosa - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - klysmen - mesalazinum 4 g, xanthani gomma, carbomerum 934, dinatrii edetas, kalii acetas, e 224, e 211 60 mg, acqua purificata q.s. la sospensione per 60 g, per la nave. - la colite ulcerosa - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - klysmen - mesalazinum 2 g, xanthani gomma, carbomerum 934, dinatrii edetas, kalii acetas, e 224, e 211 30 mg, acqua purificata q.s. la sospensione per 30 g, per la nave. - la colite ulcerosa - synthetika

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - rektalschaum - mesalazinum 1000 mg, polysorbatum 60, alcohol cetylicus et stearylicus 9.1 mg, dinatrii edetas, propylenglycolum 3436 mg, e 223, nitrogenium, propanum et butanum et isobutanum, propellentia et ad suspensionem pro dosi. - la colite ulcerosa - synthetika

Italien - italiensk - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - metotrexato - metotrexato

Schweiz - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

dr. falk pharma ag - mesalazinum - compresse rivestite con film - mesalazinum 1000 mg, cellulosum microcristallinum, povidonum k 25, carmellosum natricum, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, acidi methacrylici et methylis methacrylatis polymerisatum 1:2, calcii stearas, talcum, macrogolum 6000, hypromellosum, silica colloidalis anhydrica, e 172 (flavum), e 171, pro compresso obducto corresp. natrium 5.18 mg. - la colite ulcerosa - synthetika

Den Europæiske Union - italiensk - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - reiezione del trapianto - immunosoppressori - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Italien - italiensk - myHealthbox

effik italia - acido folico - compresse - 400 mcg - acido folico - profilassi primaria dei difetti dello sviluppo del tubo neurale del nascituro in donne fertili, che stanno pianificando una gravidanza.